3,465 press releases in English indexed under healthcare.
MANASSAS, Va., Aug. 15, 2026 -- PureHealth Research is highlighting the growing consumer awareness of circulatory and vein wellness. Supplements for vein health are nutritional formulas that commonly feature ingredients such as Horse Chestnut and Butcher's Broom, used to help...
Multi-program deal with revenue potential of $100 million per target SAN DIEGO, Aug. 15, 2026 -- Aizen Therapeutics, an AI-native biotechnology company focused on building oral biologics, today announced a multi-program collaboration with a San Diego-based, public biotech to...
Yale-trained San Antonio plastic surgeon says corporate marketing does not overturn decades of anatomic and clinical evidence SAN ANTONIO, Aug. 14, 2026 -- As national cosmetic surgery companies and new breast implant manufacturers promote above-the-muscle breast...
The post Disney Expands its Employee Health Center Network appeared first on The Walt Disney Company.
PARK CITY, Utah, August 14, 2026--WEBs Investments Inc. (WEBs) announced today its intention to close 11 series within its Defined Volatility Sector ETFs suite of funds: WEBs Energy XLE Defined Volatility ETF, WEBs Materials XLB Defined Volatility ETF, WEBs Industrials XLI Defined Volatility ETF, WEBs Consumer Discretionary XLY Defined Volatility ETF, WEBs Consumer Staples XLP Defined Volatility ETF, WEBs Health Care XLV Defined Volatility ETF, WEBs Financial XLF Defined Volatility ETF, WEBs Tec
Vancouver, British Columbia--(August 14, 2026) - Adaptogenics Health Corp. (CSE: ADPT) ("Adaptogenics", the "Company") is pleased to announce it is launching a non-brokered private placement of up to 4,000,000 common shares (the "Shares"), at a price of $0.08 per Share for gross proceeds of up to $320,000 (the "Offering"). The Company will use the net proceeds from the Offering for general working capital.The Company may elect to close the Offering in one or more tranches. It is...
ISTANBUL, Aug. 14, 2026 -- Lema Dental Clinic, an award-winning leader in European oral healthcare, today announced a comprehensive expansion of its international patient infrastructure. Designed to accommodate the rapidly growing global demand for advanced dental implants in...
Halifax, Nova Scotia--(August 14, 2026) - Appili Therapeutics Inc. (TSX: APLI) (OTC Pink: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the first quarter of its fiscal year 2027, which ended on June 30, 2026. All figures are in Canadian dollars unless otherwise stated."While ATI-1801 remains the Company's principal near-term...
BOSTON, Aug. 14, 2026 -- GuideAI Health Corp. ("GuideAI" or the "Company") (Cboe CA: GDAI) (FSE: ZN0) is pleased to announce its common shares are now posted on the Frankfurt Stock Exchange (“FSE”) under the symbol “ZN0”, WKN: A42EHA, and ISIN: CA CA40173G1019.
VANCOUVER, British Columbia, Aug. 14, 2026 -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) (the “Company” or “Optimi”), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced that it has entered into a common shares purchase agreement (the “Purchase Agreement”) with Seven Knots, LLC (“Seven Knots”), establishing an equity line of credit (the “ELOC”) under which the Company has the right, but not the obligation, to sell to Seven Knots up to US$100 million of its common shares from time to time over the term of the facility.
LONDON, August 14, 2026--Silence Therapeutics plc, (Nasdaq: SLN), ("Silence" or the "Company"), a global clinical-stage biotechnology company developing novel short interfering RNA ("siRNA") therapies, today announced the closing of its previously announced underwritten public offering of 14,907,407 American Depositary Shares ("ADSs"), each representing three ordinary shares of £0.05 each in the capital of the Company, in the United States at a public offering price of $13.50 per ADS, which incl
MINNEAPOLIS, MN, US, Aug. 14, 2026 -- PetVivo Holdings, Inc. (OTCQX: PETV), in cooperation with its wholly owned subsidiaries, Cosmeta Corp, PetVivo Animal Health, Inc. and PetVivo AI, Inc., a leading provider of medical devices and biomedical therapeutics for equines and companion animals, reported financial and operational results for the first quarter of its fiscal year ended June 30, 2026.